288 related articles for article (PubMed ID: 8911984)
1. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells.
Kramer W; Müller G; Geisen K
Horm Metab Res; 1996 Sep; 28(9):464-8. PubMed ID: 8911984
[TBL] [Abstract][Full Text] [Related]
2. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride.
Kramer W; Müller G; Girbig F; Gutjahr U; Kowalewski S; Hartz D; Summ HD
Biochim Biophys Acta; 1994 May; 1191(2):278-90. PubMed ID: 8172913
[TBL] [Abstract][Full Text] [Related]
3. The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels.
Kramer W; Müller G; Girbig F; Gutjahr U; Kowalewski S; Hartz D; Summ HD
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S67-80. PubMed ID: 8529521
[TBL] [Abstract][Full Text] [Related]
4. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics.
Müller G; Hartz D; Pünter J; Okonomopulos R; Kramer W
Biochim Biophys Acta; 1994 May; 1191(2):267-77. PubMed ID: 8172912
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of K+ channels and stimulation of insulin secretion by the sulfonylurea, glimepiride, in relation to its membrane binding in pancreatic islets.
Schwanstecher M; Mnner K; Panten U
Pharmacology; 1994 Aug; 49(2):105-11. PubMed ID: 7972319
[TBL] [Abstract][Full Text] [Related]
7. Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets.
Panten U; Burgfeld J; Goerke F; Rennicke M; Schwanstecher M; Wallasch A; Zünkler BJ; Lenzen S
Biochem Pharmacol; 1989 Apr; 38(8):1217-29. PubMed ID: 2650685
[TBL] [Abstract][Full Text] [Related]
8. A novel enhancer of insulinotrophic action by high glucose (JTT-608) stimulates insulin secretion from pancreatic beta-cells via a new cellular mechanism.
Itabashi N; Okada K; Muto S; Fujita N; Ohta T; Miyazaki Ji ; Asano Y; Saito T
J Pharmacol Exp Ther; 2001 Jun; 297(3):953-60. PubMed ID: 11356916
[TBL] [Abstract][Full Text] [Related]
9. Characterization of low-affinity binding sites for glibenclamide on the Kir6.2 subunit of the beta-cell KATP channel.
Gros L; Virsolvy A; Salazar G; Bataille D; Blache P
Biochem Biophys Res Commun; 1999 Apr; 257(3):766-70. PubMed ID: 10208857
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a mutant sulfonylurea receptor SUR2B with high affinity for sulfonylureas and openers: differences in the coupling to Kir6.x subtypes.
Hambrock A; Löffler-Walz C; Russ U; Lange U; Quast U
Mol Pharmacol; 2001 Jul; 60(1):190-9. PubMed ID: 11408614
[TBL] [Abstract][Full Text] [Related]
11. Insulin secretion and its modulation by antiarrhythmic and sulfonylurea drugs.
Horie M; Ishida-Takahashi A; Ai T; Nishimoto T; Tsuura Y; Ishida H; Seino Y; Sasayama S
Cardiovasc Res; 1997 Apr; 34(1):69-72. PubMed ID: 9217874
[TBL] [Abstract][Full Text] [Related]
12. Characterization of sulfonylurea receptors in isolated human pancreatic islets.
Giannaccini G; Lupi R; Trincavelli ML; Navalesi R; Betti L; Marchetti P; Lucacchini A; Del Guerra S; Martini C
J Cell Biochem; 1998 Nov; 71(2):182-8. PubMed ID: 9779817
[TBL] [Abstract][Full Text] [Related]
13. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
Clark HE; Matthews DR
Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
[TBL] [Abstract][Full Text] [Related]
14. Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity.
Kawaki J; Nagashima K; Tanaka J; Miki T; Miyazaki M; Gonoi T; Mitsuhashi N; Nakajima N; Iwanaga T; Yano H; Seino S
Diabetes; 1999 Oct; 48(10):2001-6. PubMed ID: 10512365
[TBL] [Abstract][Full Text] [Related]
15. Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide.
Masuda K; Okamoto Y; Tsuura Y; Kato S; Miura T; Tsuda K; Horikoshi H; Ishida H; Seino Y
Diabetologia; 1995 Jan; 38(1):24-30. PubMed ID: 7744225
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacology of glimepiride].
Satoh Y
Nihon Rinsho; 1997 Nov; 55 Suppl():147-51. PubMed ID: 9434459
[No Abstract] [Full Text] [Related]
17. Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands.
Winkler M; Stephan D; Bieger S; Kühner P; Wolff F; Quast U
J Pharmacol Exp Ther; 2007 Aug; 322(2):701-8. PubMed ID: 17495126
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes.
Müller G; Geisen K
Horm Metab Res; 1996 Sep; 28(9):469-87. PubMed ID: 8911985
[TBL] [Abstract][Full Text] [Related]
19. Extrapancreatic effects of sulfonylureas--a comparison between glimepiride and conventional sulfonylureas.
Müller G; Satoh Y; Geisen K
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S115-37. PubMed ID: 8529504
[TBL] [Abstract][Full Text] [Related]
20. Sulfonylurea receptors and mechanism of sulfonylurea action.
Panten U; Schwanstecher M; Schwanstecher C
Exp Clin Endocrinol Diabetes; 1996; 104(1):1-9. PubMed ID: 8750563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
